scispace - formally typeset
C

Cristina de Ramón

Researcher at Spanish National Research Council

Publications -  15
Citations -  187

Cristina de Ramón is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 4, co-authored 5 publications receiving 52 citations.

Papers
More filters
Journal ArticleDOI

Comparative reductions of bacterial indicators, bacteriophage-infecting enteric bacteria and enteroviruses in wastewater tertiary treatments by lagooning and UV-radiation.

TL;DR: It is demonstrated that somatic coliphages are effective indicators of enteric viruses in both of the WWTPs studied, and met the established regulations of both local and national authorities for the disposal or reuse of wastewater in irrigation for non-human crop.
Journal ArticleDOI

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

TL;DR: In this paper, a review summarizes the main genetic abnormalities described in multiple myeloma (MM) together with their prognostic impact, and the therapeutic approaches potentially aimed at abrogating the undesirable pathogenic effect of each alteration.
Journal ArticleDOI

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

TL;DR: While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality.
Journal ArticleDOI

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

TL;DR: Risk factors, antiviral treatment and outcomes of SARS-CoV-2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry are described.
Journal ArticleDOI

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

TL;DR: Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021, but results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.